Benjamin L. Lampson - Concepedia

Author

Benjamin L. Lampson

Also Known As

Benjamin L Lampson, Benjamin L. Lampson, Benjamin Lampson, Benjamin. Lampson, Benjamin L. Lampson, Nicchitta, Christopher V.

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Beth Israel Deaconess Medical Center Brigham and Women's Hospital Duke Medical Center

About

Benjamin L. Lampson is an author at Dana-Farber Cancer Institute specializing in medicine, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	504
2	Cell Biology	5	5	244
3	Natural Sciences	1	1	44
4	Public Health	1	1	10
5	Biomolecular Engineering	1	1	44

Benjamin L. Lampson

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity Benjamin L. Lampson, Siddha Kasar, Tiago R. Matos, Blood	2016	284
Rare Codons Regulate KRas Oncogenesis Benjamin L. Lampson, Nicole L. Pershing, Joseph A. Prinz, Current Biology GeneticsGenomic MechanismGene RegulationMolecular GeneticsGene Expression	2012	150
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes Christopher G. Duncan, Patrick Killela, Cathy A. Payne, Oncotarget	2010	117
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineHematology	2021	100
Rare codons capacitate Kras-driven de novo tumorigenesis Nicole L. Pershing, Benjamin L. Lampson, Jason A. Belsky, Journal of Clinical Investigation ChromatinSystems BiologyRare CodonsRare Codon BiasSomatic Variant	2014	78
Targeting eNOS in Pancreatic Cancer Benjamin L. Lampson, Stephan D. Kendall, Brooke B. Ancrile, Cancer Research Human Xenograft ModelsPancreatic CancerGastrointestinal OncologyNos IiiXenograft Models	2012	73
Targeting oncoproteins with a positive selection assay for protein degraders Vidyasagar Koduri, Leslie Duplaquet, Benjamin L. Lampson, Science Advances Protein DegradersDrug TargetMolecular RegulationMolecular BiologyTumor Biology	2021	44
Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κB Benjamin L. Lampson, Ana S. Ramίrez, Marta Baro, Cell	2024	39
Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma Nilay S. Sethi, Osamu Kikuchi, James M. McFarland, JCI Insight Esophageal CancerPathologyCancer BiologyTumor BiologyMutant P53	2019	33
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Benjamin L. Lampson, Svitlana Tyekucheva, Jennifer L. Crombie, Blood	2019	31

Page 1